La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Sansure Biotech Croissance future
Future contrôle des critères 3/6
Sansure Biotech is forecast to grow earnings and revenue by 18.7% and 26% per annum respectively. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be 6.2% in 3 years.
Informations clés
18.7%
Taux de croissance des bénéfices
18.4%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 22.5% |
| Taux de croissance des recettes | 26.0% |
| Rendement futur des capitaux propres | 6.2% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 17 May 2024 |
Mises à jour récentes de la croissance future
Recent updates
Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03
Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 2,468 | 586 | -55 | 203 | 1 |
| 12/31/2025 | 2,009 | 458 | -114 | 119 | 1 |
| 12/31/2024 | 1,496 | 329 | -431 | -109 | 1 |
| 3/31/2024 | 1,203 | 385 | -299 | 36 | N/A |
| 12/31/2023 | 1,007 | 364 | -348 | 44 | N/A |
| 9/30/2023 | 3,015 | 638 | 617 | 1,161 | N/A |
| 6/30/2023 | 4,188 | 904 | 973 | 1,523 | N/A |
| 3/31/2023 | 5,206 | 1,345 | 1,387 | 1,890 | N/A |
| 12/31/2022 | 6,450 | 1,937 | 2,000 | 2,559 | N/A |
| 9/30/2022 | 5,316 | 2,084 | 1,255 | 1,673 | N/A |
| 6/30/2022 | 5,176 | 2,247 | 1,551 | 1,963 | N/A |
| 3/31/2022 | 4,791 | 2,272 | 1,633 | 2,121 | N/A |
| 12/31/2021 | 4,515 | 2,243 | 1,504 | 1,877 | N/A |
| 9/30/2021 | 4,425 | 2,361 | 2,050 | 2,316 | N/A |
| 6/30/2021 | 4,691 | 2,506 | 2,175 | 2,404 | N/A |
| 3/31/2021 | 5,526 | 3,046 | 2,668 | 2,801 | N/A |
| 12/31/2020 | 4,763 | 2,617 | 2,534 | 2,642 | N/A |
| 9/30/2020 | 3,727 | 2,034 | 1,781 | 1,830 | N/A |
| 6/30/2020 | 2,299 | 1,263 | 1,097 | 1,150 | N/A |
| 3/31/2020 | 683 | 233 | 170 | 203 | N/A |
| 12/31/2019 | 365 | 39 | -12 | 22 | N/A |
| 12/31/2018 | 303 | 7 | -23 | 10 | N/A |
| 12/31/2017 | 225 | -11 | N/A | -61 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 688289's forecast earnings growth (18.7% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 688289's earnings (18.7% per year) are forecast to grow slower than the CN market (21.9% per year).
Croissance élevée des bénéfices: 688289's earnings are forecast to grow, but not significantly.
Chiffre d'affaires vs marché: 688289's revenue (26% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 688289's revenue (26% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 688289's Return on Equity is forecast to be low in 3 years time (6.2%).